RecruitingPhase 3NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial

Sponsor

University of Texas Southwestern Medical Center

Enrollment

272 participants

Start Date

Jul 1, 2015

Study Type

INTERVENTIONAL

Summary

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study — called JoLT-Ca — is directly comparing two treatments for high-risk patients with early-stage non-small cell lung cancer: a minimally invasive surgery to remove part of the lung (sublobar resection) versus a non-surgical treatment called stereotactic ablative radiotherapy (SAbR), which uses very focused high-dose radiation beams to destroy the tumor without surgery. **You may be eligible if...** - You are over 18 years old - You have a biopsy-confirmed, early-stage non-small cell lung cancer with a tumor 4 cm or smaller, located on the outer part of the lung - Imaging tests show the cancer has not spread to lymph nodes or other parts of the body - A thoracic surgeon confirms the tumor can be removed with a partial lung removal - You are considered high-risk for major lung surgery (due to reduced lung function, heart problems, older age, or other factors) **You may NOT be eligible if...** - You are under 18, or your tumor is larger than 5 cm - Your tumor is located near the center of the chest (not the outer edge) - The cancer has spread to other parts of your body - You have previously had lung surgery or chest radiation on the same side - You have already had chemotherapy or radiation specifically for this lung cancer - You are pregnant or breastfeeding - You had another invasive cancer within the past 3 years (except minor skin cancers) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELung Surgery

Sublobar Lung Resection

RADIATIONRadiation therapy

Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions

Locations(50)

UCSD

La Jolla, California, United States

University of Colorado/Memorial

Aurora, Colorado, United States

Penrose Cancer Center

Colorado Springs, Colorado, United States

Boca Raton Regional Hospital

Boca Raton, Florida, United States

Curtis and Elizabeth Anderson Cancer

Savannah, Georgia, United States

University of Iowa

Iowa City, Iowa, United States

University of Kansas Medical Center

Kansas City, Kansas, United States

University of Kentucky Health Care

Lexington, Kentucky, United States

University of Louisville Physicians

Louisville, Kentucky, United States

Ochsner Medical Center

New Orleans, Louisiana, United States

Luminis Health Research Institute

Annapolis, Maryland, United States

University of Maryland Medical Center

Baltimore, Maryland, United States

Boston Medical Center

Boston, Massachusetts, United States

Henry Ford Health System

Detroit, Michigan, United States

Beaumont

Royal Oak, Michigan, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Meridian Health System

Neptune City, New Jersey, United States

New York University Langone Medical Center

New York, New York, United States

SUNY - Upsate Medical Centre

Syracuse, New York, United States

University of North Carolina

Chapel Hill, North Carolina, United States

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

University of Cincinnati

Cincinnati, Ohio, United States

Case Western (University Hospitals Case Medical Center)

Cleveland, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Providence Health & Services/Oregon Clinic

Portland, Oregon, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Allegheny

Pittsburgh, Pennsylvania, United States

UPMC Health System

Pittsburgh, Pennsylvania, United States

Mount Nittany

State College, Pennsylvania, United States

Lifespan Oncology Clinical Research

Providence, Rhode Island, United States

University of Tennessee Health Science Center

Memphis, Tennessee, United States

Cardiothoracic and Vascular Surgeons

Austin, Texas, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

Intermountain Medical Center

Salt Lake City, Utah, United States

University of Virginia Health System

Charlottesville, Virginia, United States

Inova Fairfax Medical Campus

Falls Church, Virginia, United States

Swedish Cancer Institute

Seattle, Washington, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Clement Zablocki VA Medical Center

Milwaukee, Wisconsin, United States

St. Vincent's Hospital Melbourne

Fitzroy, Melbourne, Australia

St. Vincent's/Peter Mac

Fitzroy, Victoria, Australia

Barwon Health - Uni Hospital Geelong

Geelong, Victoria, Australia

Trillium Health Partners

Mississauga, Canada, Canada

Sunnybrook Health Sciences Centre

Toronto, Canada, Canada

Ottawa Hospital Cancer Center

Ottawa, Ontario, Canada

UHN-Toronto

Toronto, Ontario, Canada

Lawson Health Science Center

London, Ontario, Canada, Canada

CHUM

Montreal, Quebec, Canada

The James Cook University Hospital

Middlesbrough, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02468024